Chemotherapy plus Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor versus EGFR-TKI alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
作者
Xiaohan Qin,Yaru Guo,Xiaojin Wu,Zexian Wang,Zhiling Wan,Chen Liu
eview question / Objective The objective of this systematic review and meta-analysis was to assess and contrast the efficacy and safety of combining Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor plus Chemotherapy with EGFR-TKI alone in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Condition being studiedWe searched all the eligible studies of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor plus Chemotherapy versus control group without Chemotherapy in the treatment of advanced nonsmall cell lung cancer (NSCLC),which were retrieved from CNKI, Wanfang database, CBM, VIP, PubMed, EMBase, Cochrane Library, Web of Science.Quality evaluation was assessed by the Cochrane Collaboration's tool for randomized c o n t r o l l e d t r i a l s a n d m e t h o d o l o g i c a l index(MINORS) for non-randomized trials.Metaanalysis was con-ducted by RevMan5.3 soft ware after date extraction. METHODS Participant or population Patients diagnosed with EGFR mutation-positive non-small-cell lung cancer by histopathology and cytology. Intervention Epidermal Growth Factor Receptor ( E G F R ) -Ty r o s i n e K i n a s e I n h i b i t o r p l u s Chemotherapy.Comparator Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor alone. Study designs to be included Clinical trials (RCT).